Prostate artery embolisation: an initial experience from an Indian perspective

Abstract

PurposeThe study aims to report our very early experience with prostate artery embolisation in patients with benign prostatic hypertrophy (BPH) in an Indian setting.Material and methodsThis prospective study was approved by the Institutional Ethical Review Board, and informed consent was obtained from all the patients. Four patients with lower urinary tract symptoms due to benign prostatic hyperplasia underwent prostate embolisation. Embolisation was performed using polyvinyl alcohol (PVA) particles. International Prostate Symptom Score (IPSS), quality of life (QOL) score, postvoid residual volume, and prostate volume was recorded in each patient for 12 months. No major complications were seen in any patient.ResultsFour patients with a mean age of 74.2 years underwent prostate artery embolisation. It was successful in all the cases. Bilateral embolisation was performed in three patients and unilateral approach in one patient. Clinical improvement was characterised by a mean prostate volume reduction of 22% and mean IPSS reduction of 30% at 12-month follow-up.ConclusionsThe initial experience with prostate embolisation has been very rewarding and is a great alternative treatment for BPH. It is a very safe and effective procedure and can be an ideal procedure from an Indian perspective.

Prostate Artery Embolization—Review of Indications, Patient Selection, Techniques and Results

“…Prior to the procedure, a prophylactic dose of antibiotics is given (often either ciprofloxacin (400 mg) or ceftriaxone (2 g) via IV) [ 28 , 48 , 51 ]. Fluids (0.9% NS) are run at 100 mL/h throughout the procedure.…”

Prostate Artery Embolisation as a Palliative Care in a Patient with Prostate Cancer: A Case Report

“…It is usually performed by an interventional radiologist and forms an alternative to a TURP (trans urethral resection of prostate) operation. Prostate artery embolisation (PAE) is a safe and effective procedure and has proved its efficacy in the treatment of Benign prostatic hyperplasia (BPH) [1].…”